A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 EFFICACY STUDY OF AN AD26.RSV.PREF-BASED VACCINE IN THE PREVENTION OF LOWER RESPIRATORY TRACT DISEASE CAUSED BY RSV IN ADULTS AGED 60 YEARS AND OLDER

Intervention/treatment:
VAC18193 (JNJ-64400141/JNJ-64213175 (AD26/PROTEIN PREF RSV VACCINE))
Medical condition:
LOWER RESPIRATORY TRACT INFECTION
Protocol code:
VAC18193RSV3001
Control number:
254052
Status:
Closed
Approved:
July 23, 2021
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT04908683
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
60 Years and older
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
Clinical Franchise Leader
Organization
Janssen Vaccines & Prevention B.V.
Phone:
844-434-4210
Sponsor
JANSSEN VACCINES & PREVENTION B.V.

Locations

British Columbia

Okanagan Clinical Trials
Kelowna, British Columbia, V1Y 1Z9

Ontario

LMC Clinical Research dba Manna Research Inc. Burlington
Burlington, Ontario, L7R 1E2
LMC Clinical Research dba Manna Research Inc. Toronto
Toronto, Ontario, M9W 4L6
LMC Clinical Research Inc. (Bayview)
Toronto, Ontario, M4G 3E8

Quebec

DIEX Recherche Joliette Inc.
Saint-Charles-Borromée, Quebec, J6E 2B4
DIEX Recherche Quebec Inc.
Québec, Quebec, G1N 4V3
DIEX Recherche Sherbrooke Inc
Sherbrooke, Quebec, J1L 0H8
DIEX Recherche Victoriaville Inc.
Victoriaville, Quebec, G6P 6P6
LMC Clinical Research dba Manna Research Inc. Montreal
Pointe-Claire, Quebec, H9R 4S3
LMC Clinical Research dba Manna Research Inc. Quebec City
Lévis, Quebec, G6W 0M5

Results

See the results from the trial NCT04908683. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?